Bicara Therapeutics Future Growth
Future criteria checks 0/6
Bicara Therapeutics's earnings are forecast to decline at 30.6% per annum while its annual revenue is expected to grow at 100.3% per year. EPS is expected to grow by 34.8% per annum. Return on equity is forecast to be -125.9% in 3 years.
Key information
-30.6%
Earnings growth rate
34.8%
EPS growth rate
| Biotechs earnings growth | 28.5% |
| Revenue growth rate | 100.3% |
| Future return on equity | -125.9% |
| Analyst coverage | Low |
| Last updated | 13 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -140 | -142 | -115 | 3 |
| 12/31/2025 | N/A | -96 | -98 | -88 | 3 |
| 12/31/2024 | N/A | -68 | -74 | -64 | 3 |
| 9/30/2024 | N/A | -59 | -53 | -53 | N/A |
| 6/30/2024 | N/A | -65 | -47 | -46 | N/A |
| 3/31/2024 | N/A | -58 | -46 | -46 | N/A |
| 12/31/2023 | N/A | -52 | -46 | -46 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCAX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCAX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCAX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BCAX is forecast to have no revenue next year.
High Growth Revenue: BCAX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BCAX is forecast to be unprofitable in 3 years.